Synthetic biology market seen reaching $78.16 billion by 2034

Polaris Market Research says the synthetic biology market was worth $18.73 billion in 2025 and is projected to hit $78.16 billion by 2034. The report points to faster adoption in healthcare, industrial biotech and agriculture as AI, cheaper DNA synthesis and government funding expand commercial use.

Why it matters: - Synthetic biology is moving from a research niche into a cross-industry manufacturing platform. - The shift could reshape how companies make drugs, materials, food ingredients and chemicals. - The market outlook signals rising demand for tools and platforms that engineer living systems at scale.

What happened: - Polaris Market Research published a new synthetic biology market study on June 9, 2026. - The report values the market at $18.73 billion in 2025. - The report projects the market will reach $78.16 billion by 2034. - The report forecasts a 17.2% compound annual growth rate from 2026 to 2034.

The details: - The report says biological engineering, DNA synthesis, CRISPR-based gene editing and AI-driven design are changing how living systems are built and used. - The report links market growth to higher research spending, stronger demand for bio-based products and wider use of synthetic DNA and genome editing tools. - The report segments the market by product, technology, application and region. - Product segments include oligonucleotide and oligo pools, synthetic DNA, enzymes, cloning technology kits, xeno-nucleic acids and chassis organisms. - Technology segments include NGS, PCR, genome editing, bioprocessing and other technologies. - Application segments include healthcare and non-healthcare. - Regional coverage includes North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.

Between the lines: - Four forces are driving commercial adoption: AI, lower DNA synthesis costs, sustainability goals and government funding. - AI is shortening discovery cycles and improving biological system design. - AlphaFold changed protein structure work, and AI-designed genetic circuits are entering pipelines. - Biofoundry models let companies run more design-build-test-learn cycles in parallel. - Falling DNA synthesis costs are lowering entry barriers for startups and smaller research groups. - Sustainability pressure is pushing companies toward bio-based chemicals, fuels, plastics, textiles and food ingredients. - Public programs in the US, Europe and the UK are treating synthetic biology as a strategic area. - The report says healthcare remains the largest revenue source today. - Industrial biotechnology is one of the fastest-growing non-pharma segments. - Agriculture is gaining traction through nitrogen-fixing microbes, disease-resistant crops and lab-grown food ingredients. - The report flags biosecurity, regulatory fragmentation, public acceptance and scale-up economics as key constraints. - US oversight is split among the FDA, EPA and USDA. - Europe adds complexity through contained-use and deliberate-release rules. - Dual-use concerns are leading to tighter screening standards and export controls. - Lab-to-manufacturing scale-up remains expensive, and fermentation yield optimization is still a bottleneck.

What’s next: - The report expects North America to keep leading on revenue and innovation. - The report expects Asia-Pacific to grow fastest as governments expand biotech and manufacturing investment. - Europe is likely to keep building strength in industrial biotech and bio-based chemicals. - M&A activity is increasing as large pharma and chemical companies buy synbio platforms to secure supply chains and therapeutic pipelines. - The report says investors, drugmakers, industrial chemical companies and government stakeholders are tracking the sector closely.

The bottom line: - Synthetic biology is becoming a commercial market built on software-like design, lower-cost DNA tools and manufacturing demand, but regulation and scale-up still limit how fast it can grow.